Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

September 9th 2023

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Survival Outcomes May Be Impacted By Socio-Racial Factors in Primary Myelofibrosis

September 8th 2023

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

Treatment Approaches for High-Risk Patients With PV

September 8th 2023

Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.

Key Trials in the Treatment of PV

September 8th 2023

Experts review critical trial data in the treatment of patients with polycythemia vera.

Health Outcomes in Hematologic Malignancies Impacted By Insurance, Marital, and Economic Status

September 7th 2023

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS

September 7th 2023

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

Prognostic Model Could Help Predict Survival Outcomes for Patients With Myelofibrosis Undergoing AlloHCT

September 6th 2023

A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Renin Angiotensin Inhibitors Reduce Thrombotic Adverse Effects in Chronic Myeloproliferative Neoplasms

September 5th 2023

Patients with essential thrombocythemia and polycythemia vera who also had arterial hypertension experienced a higher cumulative incidence of thrombotic adverse effects compared with those without hypertension and fewer thrombotic complications following treatment with renin angiotensin system inhibitors.

Momelotinib Could Represent Pivotal New Treatment Option in Myelofibrosis

September 1st 2023

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

September 1st 2023

Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.

Managing Toxicities of Hydroxyurea in Patients With PV

September 1st 2023

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

August 29th 2023

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

August 29th 2023

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis stimulating agent (ESA) use in adult patients with very low– to intermediate-risk myelodysplastic syndrome (MDS) who may require regular red blood cell (RBC) transfusions.

Dr Halpern on the Investigation of Upfront Ruxolitinib and Navitoclax in Myelofibrosis

August 28th 2023

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Komrokji Examines Differences Between the WHO and ICC MDS Criteria

August 28th 2023

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

Dr Kremyanskaya on the Safety of Rusfertide in Phlebotomy-Dependent PV

August 25th 2023

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

August 25th 2023

Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.

Reducing Risk of Thrombosis in Patients With PV

August 25th 2023

Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.

Dr Kremyanskaya on the Promise of Rusfertide in Phlebotomy-Dependent PV

August 24th 2023

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.